Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | SLC10A2 | Q12908 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19046392 | 1.00 | NR1H4 (0.87) | NR1H4KMT2AATMSLC10A2 | |
| SCHEMBL920662 | 1.00 | NR1H4 (0.87) | NR1H4KMT2AATMSLC10A2 | |
| SCHEMBL19807064 | 1.00 | NR1H4 (0.87) | NR1H4KMT2AATMSLC10A2 | |
| SCHEMBL19034754 | 0.96 | NR1H4 (0.81) | NR1H4SLC10A2 | |
| SCHEMBL919592 | 0.96 | NR1H4 (0.81) | NR1H4SLC10A2 | |
| SCHEMBL5743901 | 0.95 | NR1H4 (0.79) | NR1H4SLC10A2 | |
| SCHEMBL19034768 | 0.94 | NR1H4 (0.85) | NR1H4KMT2AATMSLC10A2 | |
| SCHEMBL919383 | 0.94 | NR1H4 (0.85) | NR1H4KMT2AATMSLC10A2 | |
| SCHEMBL2692504 | 0.94 | NR1H4 (0.85) | NR1H4KMT2AATMSLC10A2 | |
| SCHEMBL919911 | 0.94 | NR1H4 (0.87) | NR1H4KMT2AATMSLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3777864-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | Albireo AB (SE) | 2021-02-17 | — | — | EP | disclosed |
| EP-3400944-B1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2020-07-15 | — | — | EP | disclosed |
| EP-3023102-B1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2018-06-27 | — | — | EP | disclosed |
| EP-3023102-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | Albireo AB (SE) | 2016-05-25 | — | — | EP | disclosed |
| EP-2637646-B1 | A PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER | ALBIREO AB (SE) | 2016-05-11 | — | — | EP | disclosed |
| EP-2637668-B1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2016-05-11 | — | — | EP | disclosed |
| WO-2012064266-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012064268-A1 | IBAT INHIBITORS FOR TREATMENT OF METABOLIC DISORDERS AND RELATED CONDITIONS | ALBIREO AB (SE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012064267-A1 | A PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER | ALBIREO AB (SE) | 2012-05-18 | — | — | WO | disclosed |
| US-20120114588-A1 | IBAT INHIBITORS FOR TREATMENT OF METABOLIC DISORDERS AND RELATED CONDITIONS | ALBIREO AB (SE) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114588-A1 | IBAT INHIBITORS FOR TREATMENT OF METABOLIC DISORDERS AND RELATED CONDITIONS | GPR119, SLC5A1, GABRQ | NR1H4 561/4885KMT2A 1542/4885ATM 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.